processa pharmaceuticals was founded in october 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. the company is headquartered in hanover, maryland.
Company profile
Ticker
PCSA
Exchange
Website
CEO
David Young
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Heatwurx, Inc.
SEC CIK
Corporate docs
Subsidiaries
Processa Therapeutics LLC ...
PCSA stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
21 Feb 24
8-K
Other Events
6 Feb 24
8-K
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
30 Jan 24
424B4
Prospectus supplement with pricing info
29 Jan 24
EFFECT
Notice of effectiveness
29 Jan 24
8-K
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
S-1/A
IPO registration (amended)
22 Jan 24
8-K
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
19 Jan 24
Transcripts
PCSA
Earnings call transcript
2022 Q4
30 Mar 23
PCSA
Earnings call transcript
2022 Q3
13 Nov 22
PCSA
Earnings call transcript
2022 Q2
14 Aug 22
PCSA
Earnings call transcript
2022 Q1
14 May 22
PCSA
Earnings call transcript
2021 Q4
31 Mar 22
PCSA
Earnings call transcript
2021 Q3
12 Nov 21
PCSA
Earnings call transcript
2021 Q2
13 Aug 21
PCSA
Earnings call transcript
2021 Q1
14 May 21
PCSA
Earnings call transcript
2020 Q3
12 Nov 20
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.86 mm | 6.86 mm | 6.86 mm | 6.86 mm | 6.86 mm | 6.86 mm |
Cash burn (monthly) | 605.49 k | 182.83 k | 722.54 k | 1.84 mm | 586.98 k | 703.07 k |
Cash used (since last report) | 3.61 mm | 1.09 mm | 4.31 mm | 10.96 mm | 3.50 mm | 4.19 mm |
Cash remaining | 3.25 mm | 5.77 mm | 2.55 mm | -4.10 mm | 3.36 mm | 2.67 mm |
Runway (months of cash) | 5.4 | 31.6 | 3.5 | -2.2 | 5.7 | 3.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 4 |
Closed positions | 7 |
Increased positions | 2 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 702.98 mm |
Total shares | 13.72 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
David Young | 11.44 mm | $45.20 mm |
Yuhan (usa) | 750.00 k | $2.96 mm |
Walleye Capital | 366.64 k | $182.40 mm |
Vanguard | 361.68 k | $179.94 mm |
Citadel Advisors | 282.84 k | $140.71 mm |
Manchester Management | 142.43 k | $819.00 k |
Geode Capital Management | 68.83 k | $34.24 mm |
Coastal Bridge Advisors | 52.50 k | $26.26 mm |
Renaissance Technologies | 45.40 k | $23.00 k |
STT State Street | 42.79 k | $21.29 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | David Young | Common Stock | Buy | Acquire P | No | No | 2.4536 | 21,000 | 51.53 k | 79,387 |
6 Feb 24 | David Young | Common Stock | Buy | Acquire P | No | No | 2.5252 | 20,000 | 50.50 k | 58,387 |
1 Feb 24 | Patrick Lin | Common Stock | Buy | Acquire P | No | No | 2.4 | 1,500 | 3.60 k | 27,478 |
31 Jan 24 | Patrick Lin | Common Stock | Buy | Acquire P | No | No | 2.37 | 2,500 | 5.93 k | 25,978 |
30 Jan 24 | Justin W Yorke | Common Stock | Buy | Acquire P | Yes | No | 2.693 | 8,000 | 21.54 k | 31,232 |
30 Jan 24 | George K Ng | Common Stock | Buy | Acquire P | Yes | No | 2.7 | 10,000 | 27.00 k | 20,000 |
News
Benchmark Reiterates Speculative Buy on Processa Pharma, Maintains $4 Price Target
6 Mar 24
How Is The Market Feeling About Processa Pharma?
9 Feb 24
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
8 Feb 24
Expensify And 3 Other Stocks Under $3 Insiders Are Buying
2 Feb 24
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
1 Feb 24
Press releases
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 24
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
25 Mar 24
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
21 Feb 24
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
14 Feb 24
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
29 Jan 24